A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] – a drug related to vitamin A – significantly cuts the risk of a second breast cancer among younger patients.
A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] – a drug related to vitamin A – significantly cuts the risk of a second breast cancer among younger patients.
